SN · Pharma and healthcare · one day
Smith & Nephew (SN): news on Monday 26 October 2026
News from the 24 hours to Monday morning, 26 October 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage centres on merger talks with J&J collapsing over a CEO dispute, which weighs on sentiment. Valuation pieces say the shares may be undervalued as the company stays independent, which partly offsets this.
What drove it
- collapsed J&J merger
- CEO dispute
- valuation upside
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Tue 20 Oct | −0.7 | 3 |
| Wed 21 Oct | +0.3 | 4 |
| Thu 22 Oct | +3.2 | 2 |
| Fri 23 Oct | −3.7 | 7 |
| Sat 24 Oct | −5.7 | 21 |
| Sun 25 Oct | −2.0 | 3 |
| Mon 26 Oct | −1.2 | 4 |
1 story · 4 headlines · strongest first
Pharma and healthcare on 26 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| Smith & Nephew's discussions on merging with J&J's orthopaedics arm fall through −4.94 headlines today · 28 in all, since 23 October · Outlets report talks collapsed over a leadership dispute. | ||
| −4.7 | Merger with J&J collapsed over CEO dispute; deal premium lost.} | |
| +4.0 | Valuation analysis says shares well below fair value despite collapse. | |
| −3.7 | Questions leadership after merger talks collapsed; uncertainty over direction. | |
| +3.0 | Stays independent; framed as modestly undervalued. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated Smith & Nephew: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.